Introduction: For a number of years concerns have been expressed locally, regionally and nationally regarding pharmacy aseptic SACT services and our ability to be able to meet the demand for aseptically prepared products. While there has been a lot of anecdotes there has not been a great amount of qualitative or quantitative data collected. Aims/objectives: A survey of those hospitals delivering IV SACT to patients across the UK has been conducted. The survey sought to collect information on the impact of delays in pharmacy on patient experience and looked to determine the degree to which the performance of commercial compounders/NHS units was affecting services to patients. Methods: The survey was distributed nationally with the help of the BOPA research and audit committee and a number of regional forums. Results/discussion: The closing date for survey submissions is 31 July 2022. Early results. 1. The survey has generated a high response rate. The response rate from hospitals in England is estimated at 85%. (110 responses from the 129 hospitals delivering SACT (Denominator taken from National SACT database)). 2. 90% of hospitals responding to the survey reported that pharmacy services had been responsible for same-day treatment delays. The predominant reason for these delays is a failure by commercial compounders to fulfil orders. 3. 60% of responders reported pharmacy was responsible for delays in treatment occurring at least weekly. 4. 66% of hospitals reported that on occasion issues in the pharmacy are responsible for patients having to have treatments rescheduled to different days. 5. Less than 50% of hospitals are currently involving the pharmacy department in decisions regarding capacity planning for SACT services. 6. 70 pharmacy departments have received complaints (formal or informal) regarding the delivery of IV SACT in the past 6 months. 7. Most senior pharmacy managers indicated high levels of concern over the delivery of pharmacy SACT services in their hospitals. All are expecting demand for IV SACT to rise in the coming years, however, none are expecting resources to deliver IV SACT to raise at similar rates. Conclusion: This survey and its results provide a very clear picture of pharmacy IV SACT services across the UK. It confirms the opinions expressed by senior pharmacy leaders that IV SACT services are extremely fragile, and without significant actions to address issues around demand, supply and workforce the situation will not improve and is highly likely to deteriorate in the coming years. Upon survey completion, the authors, with BOPA, will compile a compressive report which will contain all data collected. The aim will be to share the report widely and to use this as a means by which the current status of pharmacy IV SACT services becomes part of the national discussion about UK cancer services. [ABSTRACT FROM AUTHOR]